CY1108166T1 - Φαρμακοτεχνικη μορφη και δισκια παρατεταμενης αποδεσμευσης γουαϊφενεσινης - Google Patents
Φαρμακοτεχνικη μορφη και δισκια παρατεταμενης αποδεσμευσης γουαϊφενεσινηςInfo
- Publication number
- CY1108166T1 CY1108166T1 CY20081100686T CY081100686T CY1108166T1 CY 1108166 T1 CY1108166 T1 CY 1108166T1 CY 20081100686 T CY20081100686 T CY 20081100686T CY 081100686 T CY081100686 T CY 081100686T CY 1108166 T1 CY1108166 T1 CY 1108166T1
- Authority
- CY
- Cyprus
- Prior art keywords
- guaifenesin
- product
- release formulation
- modified release
- total amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Η εφεύρεση σχετίζεται με μία καινοφανή φαρμακευτική φαρμακοτεχνική μορφή παρατεταμένης αποδέσμευσης γουαϊφενεσίνης. Η φαρμακοτεχνική μορφή μπορεί να περιλαμβάνει ένα υδρόφιλο πολυμερές, κατά προτίμηση μία υδροξυπροπυλική μεθυλοκυτταρίνη, και ένα αδιάλυτο στο νερό πολυμερές, κατά προτίμηση μία ακρυλική ρητίνη, σε εύρος αναλογιών από περίπου ένα-προς-ένα (1:1) έως περίπου έξι-προς-ένα (6:1), κατά μεγαλύτερη προτίμηση ένα εύρος από περίπου τρία-προς-δύο (3:2) έως περίπου τέσσερα-προς-ένα (4:1), και κατά τη μεγαλύτερη προτίμηση περίπου δύο-προς-ένα (2:1), κατά βάρος. Αυτή η φαρμακοτεχνική μορφή είναι ικανή να παρέχει θεραπευτικώς αποτελεσματική βιοδιαθεσιμότητα γουαϊφενεσίνης επί τουλάχιστον δώδεκα ώρες μετά τη χορήγηση δόσης σε ένα ανθρώπινο υποκείμενο. Η εφεύρεση επίσης σχετίζεται με δισκίο γουαϊφενεσίνης τροποποιημένης αποδέσμευσης το οποίο έχει δύο τμήματα: το πρώτο τμήμα περιλαμβάνει μία φαρμακοτεχνική μορφή άμεσης αποδέσμευσης γουαϊφενεσίνης και το δεύτερο τμήμα περιλαμβάνει μία φαρμακοτεχνική μορφή παρατεταμένης αποδέσμευσης γουαϊφενεσίνης όπως περιγράφεται ανωτέρω. Αυτό το δύο τμημάτων, ή δι-στρωματικό, δισκίο έχει μία μέγιστη συγκέντρωση ορού ισοδύναμη με εκείνη ενός δισκίου γουαϊφενεσίνης άμεσης αποδέσμευσης, και είναι ικανό να παρέχει θεραπευτικώς αποτελεσματική βιοδιαθεσιμότητα γουάΐφενεσίνης επί τουλάχιστον δώδεκα ώρες μετά τη χορήγηση δόσης σε ένα ανθρώπινο υποκείμενο.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/559,542 US6372252B1 (en) | 2000-04-28 | 2000-04-28 | Guaifenesin sustained release formulation and tablets |
EP01928870A EP1276467B1 (en) | 2000-04-28 | 2001-04-26 | Guaifenesin sustained release formulation and tablets |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1108166T1 true CY1108166T1 (el) | 2014-02-12 |
Family
ID=24233984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081100686T CY1108166T1 (el) | 2000-04-28 | 2008-07-01 | Φαρμακοτεχνικη μορφη και δισκια παρατεταμενης αποδεσμευσης γουαϊφενεσινης |
Country Status (17)
Country | Link |
---|---|
US (1) | US6372252B1 (el) |
EP (2) | EP1913937A1 (el) |
JP (1) | JP2003531849A (el) |
AT (1) | ATE391494T1 (el) |
AU (2) | AU5568001A (el) |
CA (1) | CA2405031C (el) |
CY (1) | CY1108166T1 (el) |
DE (1) | DE60133538T2 (el) |
DK (1) | DK1276467T3 (el) |
ES (1) | ES2301537T3 (el) |
HK (1) | HK1052651A1 (el) |
IL (3) | IL152012A0 (el) |
MX (1) | MXPA02010556A (el) |
NZ (1) | NZ521959A (el) |
PT (1) | PT1276467E (el) |
TW (2) | TWI314866B (el) |
WO (1) | WO2001082895A2 (el) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596298B2 (en) * | 1998-09-25 | 2003-07-22 | Warner-Lambert Company | Fast dissolving orally comsumable films |
CA2328628A1 (en) * | 1999-12-21 | 2001-06-21 | Cecile J. Schoenheider | Moldable compositions |
US6955821B2 (en) | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
US8012504B2 (en) * | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US7985420B2 (en) * | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US7838032B2 (en) * | 2000-04-28 | 2010-11-23 | Reckitt Benckiser Inc. | Sustained release of guaifenesin |
US20030012820A1 (en) * | 2001-06-12 | 2003-01-16 | Upadhyay Ajay Hasmukhlal | Compressible guaifenesin compositions, method for making same and method for making compressed guaifenesin dosage forms therefrom |
BR0212950A (pt) * | 2001-09-28 | 2004-10-26 | Mcneil Ppc Inc | Formas de dosagens compósitas tendo uma porção inserida |
NZ536267A (en) * | 2002-04-10 | 2007-06-29 | Fred H Miller | Multi-phase, multi-compartment and multi-ingredient capsular system |
WO2003088952A1 (en) * | 2002-04-15 | 2003-10-30 | Adams Laboratories, Inc. | Sustained release of guaifenesin combination drugs |
PA8578501A1 (es) | 2002-07-25 | 2005-02-04 | Pharmacia Corp | Forma de dosificacion una vez al dia de pramipexol |
US7807197B2 (en) * | 2002-09-28 | 2010-10-05 | Mcneil-Ppc, Inc. | Composite dosage forms having an inlaid portion |
US20050152967A1 (en) * | 2003-03-28 | 2005-07-14 | Pfab, Lp | Dynamic variable release |
BRPI0318456B8 (pt) * | 2003-08-08 | 2021-05-25 | Biovail Laboratories Int Srl | tablete com liberação modificada |
US20050131028A1 (en) * | 2003-09-11 | 2005-06-16 | Pharmacia Corporation | Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders |
US20050096311A1 (en) * | 2003-10-30 | 2005-05-05 | Cns Response | Compositions and methods for treatment of nervous system disorders |
US20050232986A1 (en) * | 2003-12-17 | 2005-10-20 | David Brown | Dosage form containing promethazine and another drug |
US20070003622A1 (en) * | 2004-12-16 | 2007-01-04 | Sovereign Pharmaceuticals, Ltd. | Diphenhydramine containing dosage form |
US9592197B2 (en) * | 2004-12-16 | 2017-03-14 | Sovereign Pharmaceuticals, Llc | Dosage form containing diphenhydramine and another drug |
BRPI0513846A (pt) * | 2004-08-13 | 2008-05-20 | Boehringer Ingelheim Int | formulação de comprimido de liberação prolongada contendo pramipexol ou um sal farmaceuticamente aceitável do mesmo, método para a fabricação do mesmo e o uso do mesmo |
WO2006070406A1 (en) * | 2004-12-29 | 2006-07-06 | J.B. Chemicals & Pharmaceuticals Ltd | Bilayer tablets of oxcarbazepine for controlled delivery and a process of preparation thereof |
US8673352B2 (en) * | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
US20060257473A1 (en) * | 2005-05-11 | 2006-11-16 | Porranee Puranajoti | Extended release tablet |
US20070141147A1 (en) * | 2005-12-21 | 2007-06-21 | Auriga Laboratories, Inc. | Sequential release pharmaceutical formulations |
US20080064694A1 (en) * | 2006-09-11 | 2008-03-13 | Auriga Laboratories, Inc. | Multi-Phase Release Methscopolamine Compositions |
WO2008033155A1 (en) * | 2006-09-15 | 2008-03-20 | Auriga Laboratories, Inc. | Kits for prevention and treatment of rhinitis |
US20080085312A1 (en) * | 2006-10-04 | 2008-04-10 | Auriga Laboratories, Inc. | Multi-Phase Release Potassium Guaiacolsulfonate Compositions |
WO2009085306A1 (en) | 2007-12-28 | 2009-07-09 | Impax Laboratories, Inc. | Controlled release formulations of levodopa and uses thereof |
US20090202633A1 (en) * | 2008-01-03 | 2009-08-13 | Siva Ramakrishna Velaga | Extended release formulations of guaifenesin |
TWI630208B (zh) | 2008-12-08 | 2018-07-21 | 歐陸斯迪公司 | 二氫羥戊甲嗎啡 |
US20110065744A1 (en) * | 2009-09-12 | 2011-03-17 | Reckitt Benckiser Inc. | Method Of Inhibiting Mucin Secretion |
US9339478B2 (en) | 2011-02-04 | 2016-05-17 | Reckitt Benckiser Llc | Pharmaceutical formulation |
JP2011140510A (ja) * | 2011-03-17 | 2011-07-21 | Biovail Lab Inc | 塩酸ブプロピオンの放出調節錠剤 |
US20130172381A1 (en) | 2012-01-03 | 2013-07-04 | Chandrashekar Giliyar | Oral dosage forms for oxygen-containing active agents and oxyl-containing polymer |
GB201309654D0 (en) | 2013-05-30 | 2013-07-17 | Euro Celtique Sa | Method |
US10098845B2 (en) | 2013-10-07 | 2018-10-16 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
US10987313B2 (en) | 2013-10-07 | 2021-04-27 | Impax Laboratories, Llc | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
JP6184903B2 (ja) * | 2014-06-04 | 2017-08-23 | ヴァレアント インターナショナル バミューダValeant International Bermuda | 塩酸ブプロピオン放出調節錠剤 |
TWI535784B (zh) | 2014-08-26 | 2016-06-01 | 財團法人工業技術研究院 | 剪切增稠配方、及包含其之複合材料 |
US11278506B2 (en) | 2015-10-09 | 2022-03-22 | Rb Health (Us) Llc | Pharmaceutical formulation |
CN105832671A (zh) * | 2016-04-13 | 2016-08-10 | 中国药科大学 | 一种药物的缓释干混悬剂及其制备方法 |
WO2020180691A1 (en) * | 2019-03-01 | 2020-09-10 | Avadel Legacy Pharmaceuticals, Llc | Liquid guaifenesin compositions with stable extended release profiles |
US11986449B2 (en) | 2020-12-22 | 2024-05-21 | Amneal Pharmaceuticals Llc | Levodopa dosing regimen |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3065143A (en) | 1960-04-19 | 1962-11-20 | Richardson Merrell Inc | Sustained release tablet |
DE1467781A1 (de) | 1963-07-15 | 1968-12-05 | Boehringer Sohn Ingelheim | Verfahren zur Herstellung von Dragees mit verlaengerter Wirkstofffreigabe |
US3362880A (en) | 1963-09-20 | 1968-01-09 | Dow Chemical Co | Compressed drug tablets of ethyl cellulose, glyceryl monostearate, karaya gum, tragacanth, talc, and magnesium stearate |
US3555151A (en) | 1966-12-21 | 1971-01-12 | Richardson Merrell Inc | Long acting solid antacid |
US3981984A (en) | 1968-04-01 | 1976-09-21 | Colorcon Incorporated | Color film coating of tablets and the like |
US3870790A (en) | 1970-01-22 | 1975-03-11 | Forest Laboratories | Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose |
US4167558A (en) | 1976-02-13 | 1979-09-11 | Hoffmann-La Roche Inc. | Novel sustained release tablet formulations |
US4140755A (en) | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
US4122157A (en) | 1977-03-04 | 1978-10-24 | Richardson-Merrell Inc. | Nitrofurantoin sustained release tablet |
US4357469A (en) | 1979-06-14 | 1982-11-02 | Forest Laboratories, Inc. | Carrier base material for prolonged release therapeutic compositions |
US4226849A (en) | 1979-06-14 | 1980-10-07 | Forest Laboratories Inc. | Sustained release therapeutic compositions |
US4543370A (en) | 1979-11-29 | 1985-09-24 | Colorcon, Inc. | Dry edible film coating composition, method and coating form |
US4259314A (en) | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
US4424235A (en) | 1981-09-14 | 1984-01-03 | Hoffmann-La Roche Inc. | Hydrodynamically balanced controlled release compositions containing L-dopa and a decarboxylase inhibitor |
US4369172A (en) | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
US4389393A (en) | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
US4680323A (en) * | 1983-12-01 | 1987-07-14 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration |
US4540566A (en) | 1984-04-02 | 1985-09-10 | Forest Laboratories, Inc. | Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose |
US4695464A (en) | 1984-10-09 | 1987-09-22 | The Dow Chemical Company | Sustained release dosage form based on highly plasticized cellulose ether gels |
US4851392A (en) | 1985-02-05 | 1989-07-25 | Warner-Lambert Company | Ingestible aggregate and delivery system prepared therefrom |
JPS61286330A (ja) * | 1985-06-11 | 1986-12-16 | Teijin Ltd | 経口徐放性製剤 |
EP0227814A1 (en) | 1985-07-02 | 1987-07-08 | The Upjohn Company | Therapeutic formulations with bimodal release characteristics |
US4704285A (en) | 1985-11-18 | 1987-11-03 | The Dow Chemical Company | Sustained release compositions comprising hydroxypropyl cellulose ethers |
US4699779A (en) | 1986-02-18 | 1987-10-13 | Victor Palinczar | Waterproof sunscreen compositions |
IT1191674B (it) | 1986-03-07 | 1988-03-23 | Eurand Spa | Formulazioni per la preparazione di farmaci a rilascio prolungato adatte alla somministrazione per via orale |
US4756911A (en) * | 1986-04-16 | 1988-07-12 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4798725A (en) | 1986-06-16 | 1989-01-17 | Norwich Eaton Pharmaceuticals, Inc. | Sustained release capsule |
CH668553A5 (de) | 1987-02-02 | 1989-01-13 | Mepha Ag | Arzneimittel mit verzoegerter wirkstofffreisetzung. |
US4968508A (en) | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
ZA881301B (en) * | 1987-02-27 | 1989-10-25 | Lilly Co Eli | Sustained release matrix formulations |
US4786503A (en) | 1987-04-06 | 1988-11-22 | Alza Corporation | Dosage form comprising parallel lamine |
US5200193A (en) | 1987-04-22 | 1993-04-06 | Mcneilab, Inc. | Pharmaceutical sustained release matrix and process |
US4994276A (en) | 1988-09-19 | 1991-02-19 | Edward Mendell Co., Inc. | Directly compressible sustained release excipient |
JPH01153626A (ja) * | 1987-12-10 | 1989-06-15 | Nippon Soda Co Ltd | 徐放性球形粒子製剤 |
US4983398A (en) | 1987-12-21 | 1991-01-08 | Forest Laboratories, Inc. | Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates |
US5032406A (en) * | 1989-02-21 | 1991-07-16 | Norwich Eaton Pharmaceuticals, Inc. | Dual-action tablet |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
CA2020895C (en) | 1989-07-18 | 2004-02-17 | Jean-Pierre Sachetto | Polymer base blend compositions containing destructurized starch |
KR920004485A (ko) | 1990-08-30 | 1992-03-27 | 다니엘 에이. 스콜라 | 친수성 중합체 및 이와 상이한 친수성 물질로 이루어진 신규 조성물 |
US5098715A (en) | 1990-12-20 | 1992-03-24 | Burroughs Wellcome Co. | Flavored film-coated tablet |
US5403593A (en) | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
US5164398A (en) | 1991-04-01 | 1992-11-17 | Merck & Co., Inc. | Ibuprofen-antitussive combinations |
US5208037A (en) | 1991-04-22 | 1993-05-04 | Alza Corporation | Dosage forms comprising polymers comprising different molecular weights |
IT1250421B (it) | 1991-05-30 | 1995-04-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive. |
US5292534A (en) | 1992-03-25 | 1994-03-08 | Valentine Enterprises, Inc. | Sustained release composition and method utilizing xanthan gum and an active ingredient |
US5656296A (en) * | 1992-04-29 | 1997-08-12 | Warner-Lambert Company | Dual control sustained release drug delivery systems and methods for preparing same |
CA2150119C (en) * | 1992-11-30 | 2005-03-15 | Robert C. Cuca | Tastemasked pharmaceutical materials |
JPH06316517A (ja) * | 1993-02-22 | 1994-11-15 | Grelan Pharmaceut Co Ltd | 放出制御製剤 |
IT1264517B1 (it) | 1993-05-31 | 1996-09-24 | Ekita Investments Nv | Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati |
US5662933A (en) | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
US5451409A (en) | 1993-11-22 | 1995-09-19 | Rencher; William F. | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends |
US5395626A (en) | 1994-03-23 | 1995-03-07 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
IT1282650B1 (it) | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
JPH1017497A (ja) * | 1996-07-02 | 1998-01-20 | Takeda Chem Ind Ltd | 徐放性製剤およびその製造方法 |
US5807580A (en) | 1996-10-30 | 1998-09-15 | Mcneil-Ppc, Inc. | Film coated tablet compositions having enhanced disintegration characteristics |
WO1998022097A2 (en) * | 1996-11-20 | 1998-05-28 | Bio Advances, Llc | Controlled release matrix composition using polar polymer or monomer and poly(acrylic acid) blend |
US6210710B1 (en) | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
US5968554A (en) | 1998-07-07 | 1999-10-19 | Cascade Development, Inc. A Subsidiary Of Cardinal Health, Inc. | Sustained release pharmaceutical preparation |
-
2000
- 2000-04-28 US US09/559,542 patent/US6372252B1/en not_active Expired - Lifetime
-
2001
- 2001-04-26 CA CA2405031A patent/CA2405031C/en not_active Expired - Lifetime
- 2001-04-26 DE DE60133538T patent/DE60133538T2/de not_active Expired - Lifetime
- 2001-04-26 PT PT01928870T patent/PT1276467E/pt unknown
- 2001-04-26 DK DK01928870T patent/DK1276467T3/da active
- 2001-04-26 JP JP2001579770A patent/JP2003531849A/ja active Pending
- 2001-04-26 EP EP08001694A patent/EP1913937A1/en not_active Withdrawn
- 2001-04-26 ES ES01928870T patent/ES2301537T3/es not_active Expired - Lifetime
- 2001-04-26 EP EP01928870A patent/EP1276467B1/en not_active Expired - Lifetime
- 2001-04-26 MX MXPA02010556A patent/MXPA02010556A/es active IP Right Grant
- 2001-04-26 AU AU5568001A patent/AU5568001A/xx active Pending
- 2001-04-26 AT AT01928870T patent/ATE391494T1/de active
- 2001-04-26 AU AU2001255680A patent/AU2001255680B2/en not_active Expired
- 2001-04-26 NZ NZ521959A patent/NZ521959A/en not_active IP Right Cessation
- 2001-04-26 WO PCT/US2001/013379 patent/WO2001082895A2/en active Application Filing
- 2001-04-26 IL IL15201201A patent/IL152012A0/xx unknown
- 2001-06-29 TW TW090110126A patent/TWI314866B/zh not_active IP Right Cessation
- 2001-06-29 TW TW096102990A patent/TWI326602B/zh not_active IP Right Cessation
-
2002
- 2002-09-30 IL IL152012A patent/IL152012A/en active IP Right Grant
-
2003
- 2003-07-10 HK HK03104991A patent/HK1052651A1/xx not_active IP Right Cessation
-
2008
- 2008-04-09 IL IL190742A patent/IL190742A0/en unknown
- 2008-07-01 CY CY20081100686T patent/CY1108166T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
TWI314866B (en) | 2009-09-21 |
EP1276467B1 (en) | 2008-04-09 |
TWI326602B (en) | 2010-07-01 |
MXPA02010556A (es) | 2003-10-14 |
CA2405031C (en) | 2011-12-06 |
DK1276467T3 (da) | 2008-08-04 |
CA2405031A1 (en) | 2001-11-08 |
PT1276467E (pt) | 2008-05-15 |
AU2001255680B2 (en) | 2006-02-16 |
WO2001082895A2 (en) | 2001-11-08 |
ES2301537T3 (es) | 2008-07-01 |
NZ521959A (en) | 2004-10-29 |
HK1052651A1 (en) | 2003-09-26 |
DE60133538D1 (de) | 2008-05-21 |
EP1913937A1 (en) | 2008-04-23 |
IL190742A0 (en) | 2008-11-03 |
US6372252B1 (en) | 2002-04-16 |
EP1276467A2 (en) | 2003-01-22 |
IL152012A (en) | 2010-04-15 |
WO2001082895A3 (en) | 2002-05-23 |
ATE391494T1 (de) | 2008-04-15 |
JP2003531849A (ja) | 2003-10-28 |
AU5568001A (en) | 2001-11-12 |
DE60133538T2 (de) | 2009-07-09 |
TW200727919A (en) | 2007-08-01 |
IL152012A0 (en) | 2003-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108166T1 (el) | Φαρμακοτεχνικη μορφη και δισκια παρατεταμενης αποδεσμευσης γουαϊφενεσινης | |
BR0010498A (pt) | Composições modernas de medicamentos à base de compostos anticolinergicamente ativos e beta-miméticos | |
BR0207880A (pt) | Formulação farmacêutica, processo para preparação da mesma e uso de formulação sólida | |
IL165065A0 (en) | Pharmaceutical compositions containing roflumilastfor treatment of eye disease | |
EP1685839B8 (en) | Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist | |
SE9301171D0 (sv) | Pharmaceutical composition containing lipophilic drugs | |
HK1096034A1 (en) | A solid dosage form comprising a fibrate | |
ATE423556T1 (de) | Capsaicin-enthaltende missbrauchsichere pharmazeutische zusammensetzungen | |
CY1112260T1 (el) | Σκευασματα υδροκωδονης ελεγχομενης απελευθερωσης | |
CY1105437T1 (el) | Συνθεσεις πepιεχοντας διφωσφονικα οξεα | |
HUP0101237A1 (hu) | Elnyújtott kioldódású gyógyszerkészítmények | |
EP0552256A4 (el) | ||
HUP0302319A3 (en) | Pharmaceutical composition for oral administration of active ingredient | |
BR122012014331A8 (pt) | Formulações farmacêuticas | |
ES2156028T3 (es) | Composiciones que contienen tetrahidrolipstatina | |
WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
BR0208382A (pt) | Forma de dosagem oral contendo nicotina | |
WO2002024203A3 (en) | Controlled release formulations for oral administration | |
HUP0301390A2 (hu) | Valzartánt tartalmazó orális gyógyászati készítmény | |
BR0013719A (pt) | Dosagem oral de liberaçâo controlada, apropriada para administração oral | |
BRPI0407438A (pt) | Sistema terapêutico compreendendo amoxicilina e ácido clavulânico | |
BR0014440A (pt) | Formulações de liberação controlada oral | |
GEP20043377B (en) | Pharmaceutical Complex | |
BR0313175A (pt) | Formulações farmacêuticas compreendendo combinações de epinastina, pseudoefedrina e metilefedrina | |
SE9902938D0 (sv) | Pharmaceutical compositions |